# Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

> **NCT01159028** · PHASE1 · COMPLETED · sponsor: **Bio-Path Holdings, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Recurrent Adult Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Ph1 Positive CML

## Interventions

- **DRUG:** BP1001
- **DRUG:** BP1001 in combination with LDAC

## Key facts

- **NCT ID:** NCT01159028
- **Lead sponsor:** Bio-Path Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2017-03-30
- **Final completion:** 2017-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159028, "Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01159028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*